As filed with the U.S. Securities and Exchange Commission on October 8, 2025. Registration No. 333-_______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Soren Acquisition Corp. (Exact name of registrant as specified in its charter) ____________________ Cayman Islands 6770 98-1882094 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Cla ...

Company Performance - Nio reported fiscal second-quarter revenue of 19.01 billion Chinese yuan ($2.65 billion), representing a year-over-year increase of 9.0% and a sequential growth of 57.9% [2] - The company reported an adjusted loss per share of 1.85 yuan (25 cents), an improvement from a loss of 2.21 yuan in the same quarter last year, and better than analysts' expectations of a 30 cents loss [3] - For Q3 2025, Nio expects vehicle deliveries to be between 87,000 and 91,000 units, indicating a growth of approximately 40.7% to 47.1% compared to the same period in 2024 [3] Stock Movements - Cytokinetics, Incorporated shares surged 38% to $48.74 following positive clinical trial results for Aficamten [8] - Carisma Therapeutics, Inc. saw a 90% increase in shares to $0.4088 after announcing a $5 million investment from Ocugen [8] - United Therapeutics Corporation shares rose 39% to $422.36 after its TETON-2 study met primary efficacy endpoints [8] - CleanCore Solutions, Inc. shares dropped 58% to $2.8800 due to a PIPE agreement announcement [8] - Canopy Growth Corporation shares fell 16% to $1.5095 following a $200 million offering disclosure [8] - Celularity Inc. shares decreased by 37% to $2.4500 after receiving a Nasdaq notification regarding Form 10-Q [8] Market Overview - U.S. stocks traded lower, with the Dow Jones index down 1.08% to 45,052.65, NASDAQ down 1.60% to 21,111.52, and S&P 500 down 1.32% to 6,374.93 [1] - European shares also declined, with the eurozone's STOXX 600 falling 1.17% and major indices in Spain, London, Germany, and France also experiencing losses [7] - Asian markets closed mostly lower, with Japan's Nikkei 225 gaining slightly while other major indices in Hong Kong, China, and India fell [9]

Core Points - The Centers for Medicare & Medicaid Services (CMS) has revised the effective date of the Medicare Local Coverage Determination (LCD) for skin substitute products to January 1, 2026, which is used to treat diabetic foot ulcers and venous leg ulcers [1][3] - This action follows a January 2025 executive order by President Trump that froze all regulatory guidance not yet in effect, leading to a previous delay of the LCD's effective date by sixty days [3] - Celularity Inc. expressed support for CMS's decision, highlighting the importance of access to skin substitute products for Medicare patients to avoid serious health complications [4] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [5] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global health needs [5]